Optimi Health Achieves Highest-Purity Natural Psilocybin Extract to Date
OPTH sits 82% above its 52-week low of $3 on elevated volume (9.2× avg).
Summary
Optimi Health Corp. has achieved a new milestone with a 6% purity natural psilocybin extract, enhancing its supply capabilities for therapeutic use in Australia and clinical research in Europe.
Key Events · Product Development and Regulatory · OPTH
-
Highest Purity Psilocybin Extract Achieved
Optimi Health produced a 6% naturally derived psilocybin extract, representing its highest purity to date, through advancements in cultivation and extraction processes.
-
Enhanced Commercial Supply for Australia
The higher-purity extract strengthens the material base for the company's 5 mg psilocybin capsules, which are prescribed for treatment-resistant depression under Australia's Authorised Prescriber Scheme.
-
Supports European Clinical Research
A portion of the completed extract is earmarked to support upcoming GMP-grade clinical research programs in Europe.
-
Positive Safety Data Reported
Aggregated data from Australia's Authorised Prescriber Scheme indicates no serious adverse events have been reported among patients treated with psilocybin as of December 2025.
Analysis · OPTH · Life Sciences
Optimi Health Corp. announced a significant manufacturing milestone by producing a 6% naturally derived psilocybin extract, its highest purity to date. This achievement strengthens the company's commercial supply for patients in Australia and supports upcoming clinical research programs in Europe, reinforcing its position as a key supplier of regulated psychedelic drug products.
At the time of this filing, OPTH was trading at $5.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.9M. The 52-week trading range was $3.00 to $8.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.